BCI-540 (coluracetam)

BrainCells is outlicensing BCI-540 for the potential treatment of depression and anxiety.

BrainCells identified and selected BCI-540 to develop because of its neurogenic profile similar to antidepressants available on the market today. BCI-540 appears to act as a choline uptake enhancer.

Because it benefits from a novel mechanism that does not act on serotonin or norepinephrine receptors, BCI-540 has the potential to treat unresponsive and partially responsive patients with depression, especially in those patients that present with concomitant anxiety.

Clinical Results

Results from the Phase 2a trial suggest BCI-540 has the potential to treat a difficult-to-treat population, people with MDD who have failed previous treatments, and have a co-morbid anxiety disorder. Read press release.»